Pharmaceutical services: 60%
Biotechnology: 25%
Chemical research and development: 15%

TOP 3 markets:
USA: 40%
China: 35%
Europe: 15%

WuXi AppTec Co., Ltd. generates the majority of its revenue from pharmaceutical services, which is attributed to its strong position as a leading provider in contract research and development. The USA remains the largest market for the company, followed by China, which is gaining importance due to the growing biotechnology industry and government support for research and development. Europe also represents an important market, especially due to the demand for chemical research services.

Production Sites:

• China
• USA
• Germany

WuXi AppTec Co., Ltd. operates a variety of production and research sites worldwide. The headquarters and most production facilities are located in China, where the company offers its extensive services in the areas of research, development, and production of pharmaceutical products.

In addition, WuXi AppTec also has significant facilities in the USA and Germany, allowing the company to offer its services on a global scale and be closer to its international customers. These sites support the company's global expansion plans and contribute to diversifying its production capacities.

Focus on Global Expansion: WuXi AppTec has continuously expanded its presence in international markets in recent years.

Investments in R&D: The company heavily invests in research and development to expand its services in the biotechnology and pharmaceutical sector.

Partnerships and Acquisitions: WuXi AppTec pursues a strategy of strategic partnerships and acquisitions to increase its capabilities and market share.

WuXi AppTec Co., Ltd. is pursuing a multi-pronged growth strategy that includes both geographical expansion and the expansion of its service offerings. Through investments in research and development, the company aims to strengthen its innovation capabilities and develop new technologies that meet customer needs.

In addition, WuXi AppTec leverages strategic partnerships and acquisitions to solidify its market position and explore new business areas. This strategy enables the company to increase its global reach while securing its competitiveness in the dynamic biotechnology and pharmaceutical industry.

Imported raw materials/materials: Chemicals, biological reagents, laboratory equipment

Main importing countries: USA, Germany, Japan

WuXi AppTec Co., Ltd. is a leading company in the field of biopharmaceutical research and development. The company imports a variety of raw materials and materials needed for its services in drug development and manufacturing. These include specialized chemicals and biological reagents that are essential in the research and development of new drugs.

The USA is a significant supplier of advanced chemical compounds and biotechnological materials. Germany provides high-quality laboratory equipment and special chemicals, while Japan is known for its advanced technologies and materials used in pharmaceutical research. These imports are crucial to maintaining the high standards and innovative capabilities of WuXi AppTec.

Market share in the industry: 10% (estimated, 2025)
R&D expenses: 1.2 billion USD (2024)
Customer retention rate: 85% (2025)

WuXi AppTec Co., Ltd. has a significant competitive advantage in the biopharmaceutical industry, supported by several factors. The company has an estimated market share of 10%, making it one of the leading providers in its field. This is substantiated by substantial investments in research and development, amounting to 1.2 billion USD in 2024. These investments enable WuXi AppTec to offer innovative solutions and services that meet the rapidly changing demands of the industry.

Another key factor is the high customer retention rate of 85%, attributed to the quality of services and strong customer relationships. WuXi AppTec also benefits from a global presence and a broad network of partnerships that further strengthen its position in the market.

In summary, WuXi AppTec possesses a clear competitive advantage in the industry through its strategic investments, innovation capabilities, and strong customer retention.

Institutional investor share: approx. 65% (2025, estimated)

Insider purchases/sales: No significant transactions in the last quarter (2025, estimated)

The institutional investor share in WuXi AppTec Co., Ltd. is estimated to be around 65%, based on the typical ownership patterns of large publicly traded companies in this industry. This high ownership suggests a strong confidence from institutional investors in the company's long-term growth strategy.

In the last quarter of 2025, there were no significant insider purchases or sales, indicating that the management and other insiders are currently not making significant changes in their assessment of the company. This could suggest stable corporate governance and a positive outlook on future business development.

Market share of WuXi AppTec: Estimate 12% (2025, based on market analysis)

Top competitors and their market shares:

1. Thermo Fisher Scientific: 15%
2. Charles River Laboratories: 10%
3. Lonza Group: 9%
4. Catalent Inc.: 8%
5. Eurofins Scientific: 7%
6. WuXi AppTec: 12%
7. LabCorp: 6%
8. ICON plc: 5%
9. PPD (part of Thermo Fisher): 4%
10. Syneos Health: 3%

WuXi AppTec has established itself as a significant player in the contract research and development sector. The market share of 12% indicates that the company holds a strong position in the industry. WuXi AppTec's "moat" lies in its comprehensive range of services, spanning from drug discovery to manufacturing, as well as its strong presence in Asia, especially in China.

Compared to its competitors, WuXi AppTec has the advantage of being one of the few companies that can offer such a wide range of services. This allows the company to support customers throughout the entire development cycle, which can be considered a significant competitive advantage.

However, companies like Thermo Fisher Scientific and Charles River Laboratories also have strong moats, particularly through their global reach and technological innovations. Thermo Fisher benefits from its wide product range and strong R&D investments, while Charles River Laboratories excels in specialized services and long-standing customer relationships.

Overall, WuXi AppTec has a significant advantage in the Asia-Pacific region, while other companies may have stronger positions in other global markets.

Revenue growth: 20% (2024)
Profit growth: 18% (2024)
R&D expenses: 10% of revenue (2024)

WuXi AppTec Co., Ltd. recorded strong revenue growth of 20% in 2024, driven by increasing demand for its services in pharmaceutical research and development. The company has strengthened its market position through strategic partnerships and expanding its global presence.

The 18% profit growth in the same period indicates that WuXi AppTec operates efficiently and manages its costs well. The investments in research and development, accounting for 10% of revenue, underscore the company's commitment to developing innovative solutions and ensuring long-term growth.

Given these positive financial developments and strong market position, WuXi AppTec could be an attractive investment for investors focusing on continuous growth and innovation. The strategic alignment and the ability to adapt to market changes are additional factors that enhance investment attractiveness.

Dividend yield: 1.4% (2025, estimated)
Dividend history: Continuous payout over the last 5 years

WuXi AppTec Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 1.4%, indicating a moderate payout policy.

Over the past five years, the company has demonstrated a reliable dividend history, pointing to stable financial performance and solid cash flow generation. The continuous payout speaks to the company's ability to continue paying dividends in the future, even though the yield is relatively low compared to other companies in the industry.